Opgen INC 10-Q quarterly reports

OpGen, Inc. has completed its strategic pivot from precision medicine to financial services and technology, reporting significant revenue from new listing sponsorship services.

OpGen, Inc. reported a significant turnaround to profitability in Q2 2025, driven by its strategic pivot to financial services and technology, despite its recent delisting from Nasdaq.

OpGen, Inc. reported a net loss of $0.4 million in Q1 2025, a significant shift from profit, as it fully transitioned from precision medicine to financial services and technology, with no revenue generated from legacy operations.

OpGen Inc. reports a significant net income for Q3 2024 driven by debt extinguishment and strategic repositioning, while legacy operations wind down.

OpGen Inc. reported its second quarter 2024 results, reflecting a significant decrease in revenue and operating expenses due to the insolvency of its subsidiaries and a strategic shift towards a potential sale or reverse merger.

OpGen, Inc. has filed an amended quarterly report to restate its Q1 2024 financials due to an accounting error related to a lease indemnification asset, resulting in a net income of $0.3 million.

OpGen Inc. reports a net income of $386,033 for the first quarter of 2024, a significant turnaround from a net loss of $5,736,603 in the same period last year, while undergoing a strategic shift.